Vir Biotechnology (VIR) EBT Margin (2018 - 2026)
Vir Biotechnology (VIR) reported EBT Margin of 432844.83% for Q1 2026, down 42885574.0% on a YoY basis from N/an in Q1 2025, and down 643940.13% sequentially from 67.21% in Q4 2025.
Vir Biotechnology (VIR) EBT Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of EBT Margin data on file, last reported at 432844.83% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 42885574.0% year-over-year to 432844.83%; the trailing twelve-month figure through Mar 2026 stood at 674.79% (up 210098.0% YoY), and the FY2025 full-year result was 638.56%, up 6639.0% from the prior year.
- EBT Margin fell to 432844.83% in Q1 2026, from 67.21% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 74.8% in Q1 2022 to a low of 432844.83% in Q1 2026.
- A 5-year average of 31861.19% and a median of 845.93% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin surged 861301 bps in 2022 and sank 42885574 bps in 2026, its largest moves.
- Tracing VIR's EBT Margin over 5 years: stood at 306.9% in 2022, then slumped by 134 bps to 719.35% in 2023, then slipped by 18 bps to 845.93% in 2024, then soared by 92 bps to 67.21% in 2025, then plunged by 643940 bps to 432844.83% in 2026.
- Business Quant data shows VIR's EBT Margin at 432844.83% in Q1 2026, 67.21% in Q4 2025, and 67905.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -432,844.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -432,844.83% |
| Dec 31, 2025 | -67.21% |
| Sep 30, 2025 | -67,905.42% |
| Jun 30, 2025 | -9,125.86% |
| Mar 31, 2025 | -3,989.08% |
| Dec 31, 2024 | -845.93% |
| Sep 30, 2024 | -8,972.27% |
| Jun 30, 2024 | -4,549.27% |
| Mar 31, 2024 | -125.73% |
| Dec 31, 2023 | -719.35% |
| Sep 30, 2023 | -6,313.98% |
| Jun 30, 2023 | -5,204.71% |
| Mar 31, 2023 | -227.44% |
| Dec 31, 2022 | -306.90% |
| Sep 30, 2022 | 58.13% |
| Jun 30, 2022 | -575.26% |
| Mar 31, 2022 | 74.80% |
| Dec 31, 2021 | 67.17% |
| Sep 30, 2021 | 106.90% |
| Jun 30, 2021 | 36.76% |